Passage Bio Stock

passagebio.comHealthcareFounded: 2018Funding to Date: $225.5MM

Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).

Register for Details

For more details on financing and valuation for Passage Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Passage Bio.

Register Today


Management Team

Jill Quigley JD
Chief Operating Officer, Operations
Gary Romano Ph.D
Chief Medical Officer
Tadataka Yamada MD
Co-Founder & Chairman
Richard Morris
Chief Financial Officer, Finance
James Wilson Ph.D
Co-Founder & Chief Scientific Advisor
Bruce Goldsmith Ph.D
Chief Executive Officer & Board Member
Alex Fotopoulos
Chief Technology Officer, Technology
Stephen Squinto Ph.D
Co-Founder, Board Member & Acting Head of R&D

Board Members

Bruce Goldsmith Ph.D
Sandip Kapadia
Thomas Woiwode Ph.D
Versant Venture Management
Liam Ratcliffe Ph.D
Stephen Squinto Ph.D
Patrick Heron
Frazier Healthcare Partners
Saqib Islam JD
Tadataka Yamada MD

Other companies like Passage Bio in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million---72 percent more than it originally planned
Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in